Table 3:

Proportion (%) of women with at least one antepartum test or intervention, stratified by randomized group assignment

	Induction of labor N = 3059	Expectant management N = 3037	P	RR (95% CI)
Fetal surveillance and imaging
Non-stress tests	10.6	31.9	<0.001	0.33 (0.30–0.37)
Contraction stress test	0.2	0.3	0.48	0.70 (0.26–1.82)
Modified biophysical profile	0.3	1.1	<0.001	0.26 (0.13–0.55)
Biophysical profile	1.1	4.0	<0.001	0.27 (0.18–0.39)
Umbilical artery Doppler	0.03	0.3	0.02	0.12 (0.02–0.99)
Fetal position	2.7	6.5	<0.001	0.41 (0.32–0.53)
Amniotic fluid index	1.4	6.3	<0.001	0.22 (0.16–0.31)
Fetal growth	1.3	4.3	<0.001	0.31 (0.22–0.44)
Laboratory testing
Complete blood count	2.7	5.9	<0.001	0.45 (0.35–0.59)
Metabolic panel	0.6	2.0	<0.001	0.29 (0.17–0.49)
Preeclampsia panel*	1.0	3.2	<0.001	0.30 (0.20–0.46)
Other†	1.7	3.0	0.001	0.57 (0.41–0.80)
Urinalysis	1.7	6.2	<0.001	0.27 (0.20–0.36)
Treatment
Analgesic‡	0.5	2.3	0.001	0.21 (0.12–0.37)
Intravenous hydration	0.5	1.8	<0.001	0.27 (0.15–0.48)
Antibiotic	0.3	0.7	0.02	0.38 (0.17–0.85)
Other medication§	0.9	2.4	<0.001	0.36 (0.23–0.56)

Data presented as %.

RR, relative risk; CI, confidence interval

^*A complete blood count and chemistry panel focused upon preeclampsia (e.g., creatinine, liver function tests).

^†Includes blood tests (e.g., such as amylase and lipase) and cultures from urine, blood, and skin.

^‡Includes medications such as acetaminophen, butalbital, and opioids.

^§Includes medications such as anti-emetics, anti-histamines, and anti-virals.